BenevolentAI Investor Conference Presentation Deck

How BenevolentAl's approach compares to industry benchmarks Deployment run for chosen disease Typical proportion of targets identified validated by lab assay 23% Time from target to candidate 2-2.5 yrs Cost from target to IND $15m Industry benchmarks based on Paul et al Nat Rev Drug Discov 2010. Potential increase in chance of a drug reaching the market vs industry benchmark >2x (based on 25% increase in PoS at each clinical stage) Potential time saved relative to industry benchmarks At least 2 yrs Potential cost benefit per IND relative to industry benchmarks $18m saving >50% ACCURACY AND EFFICIENCY TIME @ COST Higher ROCE per $ spent on R&D Benevolent 8

View entire presentation